147 related articles for article (PubMed ID: 31834082)
1. Active surveillance in stage 1 disease: standard of care independent of risk factors?
Nason GJ; Leao R; Hamilton RJ
Curr Opin Urol; 2020 Mar; 30(2):245-250. PubMed ID: 31834082
[TBL] [Abstract][Full Text] [Related]
2. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.
Tandstad T; Smaaland R; Solberg A; Bremnes RM; Langberg CW; Laurell A; Stierner UK; Ståhl O; Cavallin-Ståhl EK; Klepp OH; Dahl O; Cohn-Cedermark G
J Clin Oncol; 2011 Feb; 29(6):719-25. PubMed ID: 21205748
[TBL] [Abstract][Full Text] [Related]
3. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.
Hamilton RJ; Nayan M; Anson-Cartwright L; Atenafu EG; Bedard PL; Hansen A; Chung P; Warde P; Sweet J; O'Malley M; Sturgeon J; Jewett MAS
J Clin Oncol; 2019 Aug; 37(22):1919-1926. PubMed ID: 30802156
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T; Cohn-Cedermark G; Dahl O; Stierner U; Cavallin-Stahl E; Bremnes RM; Klepp O
Ann Oncol; 2010 Sep; 21(9):1858-1863. PubMed ID: 20142410
[TBL] [Abstract][Full Text] [Related]
6. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
[TBL] [Abstract][Full Text] [Related]
8. Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
Oldenburg J; Aparicio J; Beyer J; Cohn-Cedermark G; Cullen M; Gilligan T; De Giorgi U; De Santis M; de Wit R; Fosså SD; Germà-Lluch JR; Gillessen S; Haugnes HS; Honecker F; Horwich A; Lorch A; Ondruš D; Rosti G; Stephenson AJ; Tandstad T
Ann Oncol; 2015 May; 26(5):833-838. PubMed ID: 25378299
[TBL] [Abstract][Full Text] [Related]
9. Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option.
Hamilton RJ; Jewett MAS; Warde P; Hansen A
Eur Urol Focus; 2019 Sep; 5(5):702-703. PubMed ID: 31129064
[TBL] [Abstract][Full Text] [Related]
10. Conditional risk of relapse in patients with germ cell testicular tumors: personalizing surveillance in clinical stage 1 disease.
Goldberg H; Madhur N; Hamilton RJ
Curr Opin Urol; 2018 Sep; 28(5):454-460. PubMed ID: 29916845
[TBL] [Abstract][Full Text] [Related]
11. Role of primary retroperitoneal lymph node dissection in stage I and low-volume metastatic germ cell tumors.
Heidenreich A; Paffenholz P; Nestler T; Pfister D; Daneshmand S
Curr Opin Urol; 2020 Mar; 30(2):251-257. PubMed ID: 31972635
[TBL] [Abstract][Full Text] [Related]
12. Treatment preferences in stage IA and IB testicular seminoma: multicenter study of Anatolian Society of Medical Oncology.
Bilici A; Ozturk T; Turkmen E; Odabas H; Cihan S; Selcukbiricik F; Erdogan B; Urakci Z; Kandemir N; Bayoglu IV; Demirci U; Duran AO; Sendur MA; Yavuzer D; Harputluoglu H; Kavgaci H; Gumus M
World J Urol; 2015 Oct; 33(10):1613-22. PubMed ID: 25605506
[TBL] [Abstract][Full Text] [Related]
13. Management of clinical stage I testicular pure seminoma. Report on 42 patients and review of the literature.
Porcaro AB; Antoniolli SZ; Schiavone D; Maffei N; Bassetto MA; Curti P
Arch Ital Urol Androl; 2002 Jun; 74(2):77-80. PubMed ID: 12161941
[TBL] [Abstract][Full Text] [Related]
14. High risk NSGCT: case for surveillance.
Kakiashvili DM; Zuniga A; Jewett MA
World J Urol; 2009 Aug; 27(4):441-7. PubMed ID: 19609532
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
16. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
[TBL] [Abstract][Full Text] [Related]
17. Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Heidenreich A; Paffenholz P; Nestler T; Pfister D
Oncol Res Treat; 2018; 41(6):370-378. PubMed ID: 29772568
[TBL] [Abstract][Full Text] [Related]
18. Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis.
Nguyen CT; Fu AZ; Gilligan TD; Wells BJ; Klein EA; Kattan MW; Stephenson AJ
J Clin Oncol; 2010 Jan; 28(1):119-25. PubMed ID: 19917846
[TBL] [Abstract][Full Text] [Related]
19. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
Warde P; Specht L; Horwich A; Oliver T; Panzarella T; Gospodarowicz M; von der Maase H
J Clin Oncol; 2002 Nov; 20(22):4448-52. PubMed ID: 12431967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
